Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. (Record no. 30483039)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01867 a2200517 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518080056.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202104s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1876-4479 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1093/ecco-jcc/jjz212 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Scott, Frank I |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20210414 |
| 245 00 - TITLE STATEMENT | |
| Title | Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Journal of Crohn's & colitis |
| Date of publication, distribution, etc. | Jun 2020 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 575-587 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adalimumab |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Algorithms |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Azathioprine |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biological Products |
| General subdivision | economics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Colectomy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Colitis, Ulcerative |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cost-Benefit Analysis |
| General subdivision | statistics & numerical data |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Therapy, Combination |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gastrointestinal Agents |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunosuppressive Agents |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Infliximab |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Markov Chains |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Models, Economic |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Quality-Adjusted Life Years |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Tumor Necrosis Factor-alpha |
| General subdivision | antagonists & inhibitors |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Luo, Michelle |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Shah, Yash |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lasch, Karen |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vajravelu, Ravy K |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mamtani, Ronac |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fennimore, Blair |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gerich, Mark E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lewis, James D |
| 773 0# - HOST ITEM ENTRY | |
| Title | Journal of Crohn's & colitis |
| Related parts | vol. 14 |
| -- | no. 5 |
| -- | p. 575-587 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1093/ecco-jcc/jjz212">https://doi.org/10.1093/ecco-jcc/jjz212</a> |
| Public note | Available from publisher's website |
No items available.